Next Article in Journal
STR Profiling Reveals Tumor Genome Instability in Primary Mediastinal B-Cell Lymphoma
Previous Article in Journal
Inflammatory Indexes as Predictive Biomarkers of Postoperative Complications in Oncological Thoracic Surgery
Article

Comprehensive Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of a Real-World Healthcare Claims Database

1
Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan
2
Translational Research Support Section, National Cancer Center Hospital East, Kashiwa 277-8577, Japan
3
Department of Medical Affairs, Guardant Health Asia, Middle East, Africa, Inc., Tokyo Port City Takeshiba Office Tower 9th Floor, 1-7-1 Kaigan, Minato-ku, Tokyo 105-7590, Japan
4
Department of Outcomes and Evidence, Guardant Health, Inc., Redwood City, CA 94063, USA
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2022, 29(5), 3433-3448; https://doi.org/10.3390/curroncol29050277
Received: 19 March 2022 / Revised: 26 April 2022 / Accepted: 29 April 2022 / Published: 9 May 2022
(This article belongs to the Section Gastrointestinal Oncology)
We used a real-world database (GuardantINFORMTM) to analyze the treatment choices for patients with mCRC who underwent next-generation sequencing of circulating tumor DNA (ctDNA) using a commercially available test (Guardant360®) after first- or second-line therapy. From 18,875 patients with claims for CRC, 1064 had confirmed metastatic disease and sufficient histories for analysis (median age 59 years, 44.8% female, 44.5% left-sided). ctDNA was detectable for 997/1064 (93.7%) patients. Clinically actionable molecular profiles were present for 507/1064 (47.7%) patients, including those who had not received targeted therapy in the previous line (410/926, 44.3%). Second- or third-line targeted therapies were administered to 338/1064 patients (31.8%) and were considered matched for 193/338 (57.1%) patients. Therapies administered after testing were informed by the ctDNA results in 56.7% of patients overall (603/1064). Time to treatment discontinuation was most favorable for patients with a clinically actionable ctDNA profile who received matched therapy. This analysis demonstrates the real-world clinical value of plasma-based comprehensive genomic profiling for selecting appropriate molecular-targeted therapies in mCRC patients with disease progression after first- or second-line therapy. View Full-Text
Keywords: actionable genomic alterations; colorectal cancer; ctDNA profiling; real-world; targeted therapy actionable genomic alterations; colorectal cancer; ctDNA profiling; real-world; targeted therapy
Show Figures

Figure 1

MDPI and ACS Style

Nakamura, Y.; Olsen, S.; Zhang, N.; Liao, J.; Yoshino, T. Comprehensive Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of a Real-World Healthcare Claims Database. Curr. Oncol. 2022, 29, 3433-3448. https://doi.org/10.3390/curroncol29050277

AMA Style

Nakamura Y, Olsen S, Zhang N, Liao J, Yoshino T. Comprehensive Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of a Real-World Healthcare Claims Database. Current Oncology. 2022; 29(5):3433-3448. https://doi.org/10.3390/curroncol29050277

Chicago/Turabian Style

Nakamura, Yoshiaki, Steven Olsen, Nicole Zhang, Jiemin Liao, and Takayuki Yoshino. 2022. "Comprehensive Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of a Real-World Healthcare Claims Database" Current Oncology 29, no. 5: 3433-3448. https://doi.org/10.3390/curroncol29050277

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop